Protara Therapeutics, Inc. announced on June 2, 2025, the appointment of William 'Bill' Conkling as Chief Commercial Officer. Mr. Conkling brings over two decades of experience in developing and commercializing novel cancer and rare disease therapeutics, a critical skill set as Protara advances its pipeline.
Mr. Conkling's previous roles include President and Chief Executive Officer of Rafael Holdings, Inc., and Vice President of Commercial at Immunomedics, where he built the U.S. commercial organization for the launch of Trodelvy. He also held key leadership positions at Novartis Pharmaceuticals, contributing to the commercialization of several oncology products, including Kymriah.
This strategic hire signals Protara's preparation for a potential transition into a commercial-stage organization. Mr. Conkling's expertise in building commercial teams and launching products in oncology and rare diseases will be vital for translating clinical success into market share for Protara's differentiated therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.